OBJECTIVE: To review the use of recombinant activated factor VII in paediatric cardiac surgery. DESIGN: Retrospective chart review. SETTING: Paediatric intensive care unit in a stand-alone university-affiliated children's hospital. PATIENTS AND PARTICIPANTS: Cardiac surgical patients who received recombinant activated factor VII (rFVIIa, NovoSeven; NovoNordisk, Copenhagen, Denmark) between June 2002 and June 2003 at The Children's Hospital at Westmead. RESULTS: Six children undergoing cardiac surgery received rFVIIa. Recombinant activated factor VII was administered if bleeding was excessive and persisted despite appropriate investigation and attention to haemostasis by surgical and medical staff. An intravenous dose of 180 microg/kg was given and repeated 2 h later. All of the six patients responded well to rFVIIa with achievement of haemostasis. No adverse events were noted. CONCLUSIONS: Recombinant activated factor VII achieved haemostasis in six paediatric cardiac surgical patients. Good outcomes and no adverse events were noted in these children.
OBJECTIVE: To review the use of recombinant activated factor VII in paediatric cardiac surgery. DESIGN: Retrospective chart review. SETTING: Paediatric intensive care unit in a stand-alone university-affiliated children's hospital. PATIENTS AND PARTICIPANTS: Cardiac surgical patients who received recombinant activated factor VII (rFVIIa, NovoSeven; NovoNordisk, Copenhagen, Denmark) between June 2002 and June 2003 at The Children's Hospital at Westmead. RESULTS: Six children undergoing cardiac surgery received rFVIIa. Recombinant activated factor VII was administered if bleeding was excessive and persisted despite appropriate investigation and attention to haemostasis by surgical and medical staff. An intravenous dose of 180 microg/kg was given and repeated 2 h later. All of the six patients responded well to rFVIIa with achievement of haemostasis. No adverse events were noted. CONCLUSIONS: Recombinant activated factor VII achieved haemostasis in six paediatric cardiac surgical patients. Good outcomes and no adverse events were noted in these children.
Authors: H G Hendriks; J M van der Maaten; J de Wolf; T W Waterbolk; M J Slooff; J van der Meer Journal: Anesth Analg Date: 2001-08 Impact factor: 5.108
Authors: J Kristensen; A Killander; E Hippe; C Helleberg; J Ellegard; M Holm; J Kutti; U H Mellqvist; J E Johansson; S Glazer; U Hedner Journal: Haemostasis Date: 1996
Authors: N S Key; L M Aledort; D Beardsley; H A Cooper; G Davignon; B M Ewenstein; G S Gilchrist; J C Gill; B Glader; W K Hoots; C T Kisker; J M Lusher; C G Rosenfield; A D Shapiro; H Smith; E Taft Journal: Thromb Haemost Date: 1998-12 Impact factor: 5.249
Authors: Alex Veldman; Doris Fischer; Burkhard Voigt; Peter A Beyer; Rolf Schlösser; Antje Allendorf; Wolfhardt Kreuz Journal: Intensive Care Med Date: 2002-09-11 Impact factor: 17.440
Authors: M Al Douri; T Shafi; D Al Khudairi; E Al Bokhari; L Black; N Akinwale; M Osman Musa; A Al Homaidhi; M Al Fagih; R Borum Andreasen Journal: Blood Coagul Fibrinolysis Date: 2000-04 Impact factor: 1.276
Authors: A Chuansumrit; T Chantarojanasiri; P Isarangkura; S Teeraratkul; S Hongeng; P Hathirat Journal: Blood Coagul Fibrinolysis Date: 2000-04 Impact factor: 1.276
Authors: C A Troianos; R W Sypula; D M Lucas; F D'Amico; T B Mathie; M Desai; R T Pasqual; R V Pellegrini; M L Newfeld Journal: Anesthesiology Date: 1999-08 Impact factor: 7.892
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2005-02-18 Impact factor: 17.440